Gastric Cancer Medical Services in China

Gastric cancer, or adenocarcinoma of the stomach, is a malignant neoplasm arising from the gastric mucosa—most commonly in the distal antrum or cardia. Risk factors include chronic *Helicobacter pylori* infection, atrophic gastritis, intestinal metaplasia, dietary nitrosamines, smoking, and familial syndromes such as hereditary diffuse gastric cancer (CDH1 mutations). Early-stage disease is often asymptomatic; advanced presentations may include weight loss, hematemesis, melena, or abdominal pain. Diagnosis relies on upper gastrointestinal endoscopy with biopsy, staging via contrast-enhanced CT, EUS, and PET-CT where indicated. Treatment is multimodal: curative-intent surgery (D2 gastrectomy) remains cornerstone for resectable disease; perioperative chemotherapy (e.g., FLOT regimen) significantly improves survival. For unresectable or metastatic cases, targeted therapies (trastuzumab for HER2+, pembrolizumab for MSI-H/dMMR tumors) and immunotherapy are increasingly integrated into standard care.

China offers distinct advantages in gastric cancer management: its tertiary hospitals—especially those affiliated with Peking University Cancer Hospital, Fudan University Shanghai Cancer Center, and Sun Yat-sen University Cancer Center—rank among Asia’s top oncology institutions, with surgeons performing over 5,000 gastrectomies annually and publishing high-impact outcomes in *Annals of Oncology* and *JAMA Surgery*. Advanced technologies—including robotic-assisted laparoscopic gastrectomy, intraoperative fluorescence imaging, and next-generation sequencing–guided precision oncology—are widely deployed. Five-year overall survival for Stage II–III patients exceeds 60% in leading centers, comparable to U.S. and European benchmarks. Crucially, comprehensive treatment—including diagnostics, surgery, adjuvant therapy, and follow-up—costs 40–60% less than in the U.S., UK, or Singapore, without compromising clinical standards.

As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital accreditation, coordinating multidisciplinary tumor board reviews, securing priority appointments, providing bilingual clinical liaisons, and delivering itemized, transparent pricing—covering all services from visa support to post-treatment rehabilitation. We ensure continuity of care, not just convenience.

China offers a compelling option for gastric cancer treatment, combining advanced oncology care with significant cost savings—typically 40–60% lower than equivalent care in the U.S. or Western Europe, without compromising clinical standards. Leading Chinese hospitals, especially those affiliated with top-tier academic medical centers, utilize state-of-the-art diagnostic tools—including high-resolution endoscopy, PET-CT, and next-generation sequencing—and perform minimally invasive and robotic-assisted gastrectomies routinely. Many oncologists have trained internationally and participate in global clinical trials, ensuring adherence to NCCN and ESMO guidelines. Our agency supports patients by providing transparent, itemized pricing upfront, assisting with evidence-based hospital selection (e.g., Fudan University Shanghai Cancer Center or Peking University Cancer Hospital), and developing personalized budget plans that include treatment, accommodation, and follow-up coordination. The treatment process is streamlined: initial remote consultation, visa support, airport-to-hospital transfers, multilingual nursing assistance, and integrated postoperative monitoring—all coordinated centrally. Patients benefit from shorter wait times for surgery and multidisciplinary tumor board reviews, typically within 7–10 days of arrival. This combination of clinical rigor, technological capability, and logistical efficiency makes China a practical and reliable destination for gastric cancer care.

International Patient Treatment Process for Gastric Cancer (Oncology): After initial online or phone consultation with our medical coordinators, patients submit medical records—including endoscopy reports, biopsy pathology, imaging (CT/MRI/PET-CT), and prior treatment summaries—for pre-screening by affiliated oncologists. Once eligibility is confirmed, we schedule a virtual or in-person multidisciplinary tumor board review. Our agency handles all appointment coordination across gastroenterology, surgical oncology, medical oncology, and radiation oncology departments. We provide certified medical translators for all consultations and procedures, and assign bilingual patient liaisons for hospital accompaniment. Accommodation near the treatment facility is arranged per preference and budget, including options with kitchen access or caregiver rooms. Required materials: passport copy, medical records (translated into English if necessary), recent lab results, insurance documentation (if applicable), and visa support letters. The full process—from record submission to treatment completion—typically takes 4–8 weeks, depending on diagnostic workup, surgery scheduling, and adjuvant therapy planning. All international patients receive 24/7 multilingual support, airport transfers, medication guidance, and post-discharge follow-up coordination with home-country providers.

Medical Travel to China Guide: Gastric Cancer (Oncology)

Visa & Entry: Patients require a Chinese Medical Visa (Q2 or S2), obtainable with an invitation letter from our partnered hospitals and confirmed treatment plan—we handle all documentation and embassy coordination.

Insurance & Payment: Most international health insurance policies do not cover overseas cancer care; we advise verifying coverage in advance. Our agency provides transparent, itemized pricing—including diagnostics, surgery (e.g., laparoscopic gastrectomy), chemotherapy, and pathology—before treatment begins. We accept wire transfers, credit cards, and third-party medical financing, and assist with insurance pre-authorization where applicable.

Accommodation & Companions: We arrange hospital-adjacent apartments with kitchen access, Wi-Fi, and 24/7 support. One companion may accompany you at no extra cost for lodging; additional guests receive discounted rates.

Follow-Up Care: Post-treatment, our dedicated oncology coordinator schedules virtual consultations with your Chinese oncologist every 2–4 weeks, shares pathology reports and imaging in English, and liaises with your home-country physician to ensure seamless continuity of care—including medication refills and local surveillance protocols.